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EcoRI tagged-mixed oligonucleotide primer pairs corresponding to 
Abstract Earlier we reported the primary structure of serum the caldecrin-specific sequence (encoding amino acids 63 69) and 
calcium-decreasing factor (caldecrin) from rat pancreas, a the elastase-conserved s quence (encoding amino acids 125 131) of 
protein which is considered to be a member of the elastase rat caldecrin. The amplified product of about 200 bp was cloned 
family. In this report, we describe the isolation of the two into pUCl9, sequenced, and 32p-labeled with a Ready-To-Go DNA 
homologous cDNA clones encoding caldecrin from human labeling kit (Pharmacia Biotech). Recombinant plaques from a human 
pancreas, the structures of which are identical except for one ~.gtl 1 pancreas 5'-stretch cDNA library (Clontech) were transferred 
base and the corresponding amino acid residue. These human onto a nylon membrane (Hybond-N, Amersham), fixed with ultravio- 
let light, and hybridized with the probe in hybridization solution (50% 
caldecrin isoforms are composed of a signal peptide of 16 amino formamide, 5× SSC, 2 × Denhardt, 0.1% SDS, and 0.1 mg/ml dena- 
acids, a propeptide of 13 amino acids, and a mature form of 239 tured salmon testis DNA) at 42°C for 16 h. The membranes were 
amino acids. Both recombinant caldecrins showed the same subsequently washed twice in 2×SSC, 0.1% SDS at 25°C for 30 
chymotrypsin-type protease activity and hypocalcemic activity, min and twice in 0.2×SSC, 0.1% SDS at 50°C for 30 rain. After 
The hypocalcemic activity of both remained intact even after autoradiography, positive plaques were subcloned into pUC19 and 
treatment with PMSF to abolish their protease activity. These sequenced. 
results suggest that human caldecrin possesses hypocalcemic 
activity that has no connection with its protease activity. 2.2. Production of recombinant virus 
Production of recombinant virus (pBacHC) was performed accord- 
ing to the manual of the baculovirus expression system (Clontech) and 
Key words." Pancreas; Calcium; Elastase; Human as described previously [4]. The entire coding region of human calde- 
crin isolated from ~,gt 11 or Quick-clone cDNA library was amplified 
by PCR with two EcoRI tagged-oligonucleotides (5'- 
1. Introduction TTGAATTCATGTTGGGCATCACTGTCCTCGCTG-3') and (5'- 
TTGAATTCTCACAGCTGCATTTTCTCGTT-3'). The PCR prod- 
ucts were subcloned into pBacPAK9 transfer vector. After centrifuga- 
Acute pancreatit is causes hypocalcemia, which suggests that tion with CsC12, the purified transfer vectors carrying human calde- 
the pancreas contains hypocalcemic factors [1]. We previously crin and BacPAK6 viral DNA were cotransfected into Sf9 cells. 
reported the purification of a serum calcium-decreasing factor 
(caldecrin) from porcine and rat pancreas, and the cloning of 2.3. Expression and purification of human caldecrin 
Sf9 cells were transfected with the recombinant virus and cultured 
rat caldecrin cDNA [2-4]. The pr imary structure of the rat for 3 days. The medium containing recombinant peptide was col- 
caldecrin cDNA is, with the exception of that of the central lected, concentrated, ialyzed against 10 mM sodium phosphate bur- 
region, almost identical to that of elastase IV cDNA which fer (pH 6.8), and applied to a hydroxyapatite column, Bio-Scale CHT- 
was identified by cloning with PCR from rat pancreas, as 1 (Bio-Rad). After extensive washing, absorbed materials were eluted 
reported by Kang et al. [5]. The amino acid sequence of frag- by stepwise increases in the phosphate buffer concentration up to 0.5 
M. Caldecrin in each fraction was assayed for proteolytic activity 
ments derived from purified rat caldecrin was identical to the after trypsin activation, and caldecrin protein was detected by Wes- 
amino acid sequence deduced from rat caldecrin cDNA but tern blotting using anti-porcine caldecrin antibody. 
different from that of elastase IV, especially in the central 
region [4]. 2.4. Assay for protease activity 
Proteolytic activity of caldecrin was measured by hydrolysis of Suc- 
In this report, we isolated caldecrin cDNAs from human Ala-Ala-Pro-Phe-pNA (Peptide Institute Inc.), as described previously 
pancreas and purified the recombinant proteins produced in a [6]. 
baculovirus expression system. The recombinant human cal- 
decrin showed serum calcium-decreasing activity even after 2.5. In vivo assays 
inactivation of its protease activity. The serum calcium-decreasing activity (SCDA) was measured as 
described previously [4]. Recombinant caldecrin was activated at 
24°C for 30 min with trypsin at 1/50th of the protein amount of 
2. Materials and methods caldecrin, and the activation was terminated with 1 mM APMSF, a 
specific inhibitor of trypsin. After the activated caldecrin had been 
2.1. Screening for human caldecrin cDNA treated for an additional 10 min with or without 1 mM PMSF, the 
In order to obtain the hybridization probe, we amplified human buffer was changed to phosphate-buffered saline by use of a PD-10 
pancreas cDNA, QUICK-Clone cDNA (Clontech), by PCR with desalting column (Pharmacia Biotech). The purified recombinant hu- 
man caldecrin was injected into male Balb/C mice, and blood was 
*Corresponding author. Fax: (81) (99) 275-6278. taken 4 h after injection. Serum calcium concentration was measured 
by the o-cresolphthalein complexson method [7]. 
Abbreviations: caldecrin, serum calcium-decreasing factor; SCDA, 
serum calcium-decreasing activity; PCR, polymerase chain reaction; 3. Results and discussion 
APMSF, 4-amidinophenylmethanesulphonyl fluoride; PMSF, phenyl- 
methylsulfonyl fluoride; PAGE, polyacrylamide gel electrophoresis; 
PX, pancreatic extract We first investigated unique sequences of caldecrin for the 
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Table 1 
Sequence homology of human caldecrins with porcine (Por.), rat and human elastases 
Caldecrin Elastase 
Rat Por. Rat Por. Rat Human 
I I II I1 IIA IIB IIIA IIIB 
Human caldecrin (% of homology) 
HCI 78.0 50.8 51.5 61.1 61.3 63.4 59.6 52.2 53.0 
HC2 78.0 50.8 51.5 60.8 60.9 63.0 59.2 52.2 52.6 
The amino acid sequences deduced from human caldecrins HC1 and HC2 were compared with those of rat caldecrin [4], porcine elastase I [8], rat 
elastase I [9], porcine elastase II [10], rat elastase II [9], human elastase IIA and IIB [10], and human elastase IlIA and IIIB [11]. 
screening for caldecrin cDNA from human pancreas. When was 953 bp in length and contained a full coding region 
the pr imary structure of the deduced amino acid sequence of from the 5' -noncoding sequence to the TGA stop codon, 
rat caldecrin cDNA was compared with that of human elas- but had no poly(A) tail. The other clones appeared to lack 
tase family members, IIA, I IB [10], I I IA and II IB [11], the regions corresponding to the 5'- or Y-side of non-coding 
amino acid sequence at posit ions 63~59 of rat caldecrin ap- regions. The open reading frame of all clones was identical 
peared to be unique for caldecrin. We obtained a PCR pro- except for thymine (C) or cytosine (T) at nucleotide position 
duct carrying the unique sequence of caldecrin with the hu- 238 (nucleotide number ing commencing at the start codon) 
man pancreas Quick-Clone cDNA library, and used it as a corresponding to Arg or Trp, respectively, at amino acid se- 
probe for the screening for caldecrin cDNA from the kgt l l  quence position 51 (amino acid sequence numbering of the 
human pancreas cDNA library, mature form). Arg and Trp types of human caldecrin were 
Approx. 2× 105 transformants from the latter l ibrary were denoted HC1 and HC2, respectively; 5 out of 6 clones were 
screened with the caldecrin-specific probe. After 3 rounds of found to be HC2, the remaining one being HC1. Human 
screening, 6 positive clones (pHC) were obtained. Among caldecrin cDNA was also amplified from the QUICK-C lone 
these positive clones, pHC70 had a length of 851 bp and human pancreas cDNA library by PCR with oligonucleotide 
contained a poly(A) tail but no ATG start codon, pHC66 primers involving the start and stop codons of the open read- 
ing frame of the human caldecrin cDNA. The sequence of 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  ~ . . . . . . . . . . .  PCR product, pHCQC2/9,  was found to be the HC1 type. 
. . . . . . . . . . . . . . . . . . . . . . .  These results suggest hat there is polymorphism of caldecrin 
-1 T +1 Arc ~c cog coo ~c =,A ,~c ~:c =rA GTG GT~ ~ ~A r~ ~ ~ . . . . . .  ~ C~ Are ~0 expression in the human pancreas. The nucleotide sequence 
. . . . . . . . . . . . . . . . . . . . . .  and the pr imary structure of human caldecrin are shown in 
. . . .  ~ . . . . . . . . . . . . . . . . . . . .  ~G ~ . . . . . . . . . . . . . . . . . .  ~ . . . .  Fig. 1. The human caldecrin cDNAs,  pHC1 and pHC2, 
p Q I $ L Q Y L D T W R H T C 31 
showed an open reading frame of 807 bp, corresponding to T 
~G ~ ~ ~ ~, ~%~ ~c ~o ~V ~ ~=~ ~cf ~ S  A~ .%c ~c ~cc ~ ~,~ 239 amino acid residues with a calculated molecular mass of 
w 
Ace~c~% . . . . . .  v o ~ G ~  . . . . . . . . . . . .  ~ ~ ~ ~ ~CO~ ........... G ~ ~ ~ 
-29 ] 20 *********  *****  **  * ******  ******  * * *****  *****  
~T GTG GGT GTG GAC ACC ATC CAC GTC CAC AAG AGA TGG ~AT GCC CTC CTG TTG CGC ~N T 360 
V G V D r I H V H ~ a W N A ~ L ~ ~ 91 Human : MLGI  TVLAALLACASSCGVPSFPPNLSARVVGGEDARPHSWPWQI  S LQYL  
Rat  : MLGI  TVLAAI  LACASCCGNPAFPPNLSTRVVGGEDAVPNSWPWQVSLQYL  
@ATT GCC CTC ATC AAG CTT CCA GAG CAT GTG GAG CTG AGT GAC ACC ATC CAG GTG GCC Porc ine :  GVPSFPPNLSARVVGGENAVPHSWPWQISLQYL  4201 
I A L I K L A E H V E L S D T I Q V A 1 40 6O 
***  *****  **  ********  W****  **  **  *******  
~C CTG CCA GAG AAr SAC ~C CTG CTC CCC AAG GAC T~C CCC ~C C TAT GTC ACC GGC TGG 480 Human :KNDTWRHTCGGTL IASNFVLTAAHCISNTRTYRVAVGKNNLEVEDEEGSL 
L P E K L L P X D p ¥ V T S W 131 Rat  : KDDTWRHTCGGSL I  TTSHVLTAAHC I NKDFTYRVGLGKYNLTVEDEEGSV 
Porc ine  : SGDT KHTCGGTL I  TSTHVLTAAHX I S NSRTY KNNLEVEDEEGSL 
. . . . . . . . .  ~wG ACC A~NC G~G . . . . . . .  C~ . . . . . . . . . . . . . . .  G~ . . . . . . . . . . . . . . .  80 100 ~.2~ 
G R L P I D K L Q Q L Q P V 151 **  * **  **  * **  * *****  ****  ******  **  **  
Human : FVGVDTI  HVHKRWNALLLRNDIAL I  KLAE HVELSDTI  QVAC LPEKDSLLP  
. . . . . . . . .  C~AC ATCG ~C C TC . . . . .  I TT GAC ~W G ~W G ~ . . . . .  R G. . . . . . . . . . .  M T . . . .  Ra  t :YAEVDTIYVHEKWNRLFLWNDZAI IKLAEPV~LSNTIQVACIPEEGSLLP  v D H R F V K K T 171 
Porc ine  : VVGVDS I FV  KWNSLL IRNDPAL 
GAC @GT . . . . .  GCAT GGGG GGGC . . . . . . . . . . . .  TCsA GCAC ~C ~T GGGG CCA C~G 616901 140 160 
V C D G V I D G ~C *******************  *******  * ******  ***  * ***  
Human : KDYPCYVTGWGRLWTNGPIADKLQQGLQPWDHATC SR I  DWWGFRVKKTM 
AACN TGCc CAGQ TTGL rAGE ~C GGTG TCCs Trrw GAGE GTGv TTTr ~C ArC~ GTCv AGCs TrTr [ ]  TCCs CUGR 211720 Porcine:Rat : QDYPCYVTGWGRLWTNGP IAEVLQQGLQP IVSHATC SRLDWWF I KVRKTM 
180 200 2.20 ***********************  . * **  * *******  ***  * AAG CCr GTC TAC ACC CGG GTG TCC GCC TAC ATC GAC 780 
R G R K P V Y T R V S A Y I D 231 
Human : VCAGGDGVI  SACNGDSGGPLNCQLENGSWEVFGIVSFGSRRGCNTRKKPV 
TG G ATC C GAG A~ ATG CAG CTG TG A TTTGTTGCTGGGACCGCCGGCAGCGAGTCCCTGCAACAGC~A 840 Rat  :VCAGGDGVISACNGDSGGPLNCQA~DGSWQVHGIVSFGSSSGCNVHKKPV 
W I ~ E I~ M Q L *** -- 239 Porcine: KKPL  . * ****  ***  .2~.9 
Human : VYTRVSAYIDWINEKMQL 
TA~C r TC C TTC TCC TCGGGC ACC T G ~ J K A ~  875 Rat  : VFTRVSAYNDWI  NEK IQL  
Porc ine  : VFARVSAYIDWIDQQ 
Fig. 1. The nucleotide and deduced amino acid sequences of human 
caldecrin. The nucleotide and deduced sequences of HC2, which dif- Fig. 2. Comparison of amino acid sequences among mammalian cal- 
fer from those of HC1, are shown above and below the HC1 se- decrins. The amino acid sequence of human caldecrin HC2, which 
quence, respectively. The polyadenylation signal is underlined. The differs from that of HC1, is shown above the HC1 sequence. The 
protein sequence is indicated using the single-letter code and is se- data for the deduced full-length rat caldecrin and the partial se- 
quentially numbered from the amino-terminus of the mature form. quence of purified porcine caldecrin were reported previously [4]. 
The arrowheads indicate the proteolytic leavage sites. The amino The numbering starts from the amino-terminus of the predicted ac- 
acid residues of the charge-relay system are circled, and those for tive form of rat caldecrin. An asterisk indicates the conserved amino 
the substrate specificity are boxed, acid residue among all sequences compared. 
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and HC2 were assayed for SCDA. As shown in Fig. 3, both 
Ghymotrypsinactivib/(U/mg protein) Serum Calcium {mg/~0 HC1 and HC2 showed not only chymotrypsin activity but 
0.25 0.5 6 7 8 9 , , II . . . .  also SCDA. The protease activity and SCDA of HC1 and 
Control ]---1 HC2 were at almost the same level as those of recombinant 
j ,  
rat caldecrin. Furthermore, treatment of HC]  and HC2 with 
I ~ PMSF abolished their chymotrypsin activity, but did not af- 
HC-1 I H fect their SCDA. Thus, like the other caldecrins, human cal- 
Hc-t ]~ decrin possesses hypocalcemic activity which had no connec- 
÷PMSF ] ~ tion with its protease activity. 
[ N Hypocalcemia s associated with acute pancreatitis, and hy- 
HC-2 
I poca]cemic factors are postulated to exist in the pancreas [1]. 
HC-2 ]~ Recently, Yoneda et al. purified a hypocalcemic factor, PX, 
÷PMSF 11 from porcine pancreas, and reported that it resembled human 
elastase IIIB [12-15]. Additionally, recombinant human elas- 
* P<0.05  ~ P<0.01 
tase IIIB showed hypocalcemic activity that was connected 
Fig. 3. Comparison of the protease activities and hypocalcemic a - with its protease activity [14,15]. The primary structure of 
tivities of purified recombinant human caldecrin HC1 and HC2. Re- 
combinant human caldecrins HC1 and HC2 were treated or not human and rat caldecrins is different from that of elastase 
with PMSF and assayed for chymotrypsin activity and hypocalcemic IIIB (Table 1), the difference undoubtedly being responsible 
activity, for the difference in protease requirement for SCDA between 
caldecrins and elastase IIIB (presumably PX). Caldecrin sup- 
29327 Da. Both amino acid sequences deduced from HC1 pressed osteoclastic function as did calcitonin and this sup- 
and HC2 showed higher homology (78%) with the rat full- pressive ffect was protease activity-independent (manuscript 
length and porcine partial sequences than with other elastase in preparation). Recombinant elastase IIIB suppressed bone 
family members (Fig. 2 and Table 1). The deduced amino acid resorption in a protease activity-dependent manner [14,15]. 
sequence of human caldecrin cDNA consisted of 16 amino The reason for this difference in requirement for protease 
acid residues of the pre-sequence, 13amino acid residues of activity for the effects of caldecrin and elastase IIIB (and 
the pro-sequence, and 239 amino acid residues of the mature presumably PX) on bone metabolism is unclear. Thus, it is 
form just as that of rat caldecrin. All cysteine residues in hu- of great importance to define the mechanism of hypocalcemia 
man caldecrin were conserved at the same position as those of induction by elastase family members. 
rat caldecrin. The cysteine residue at position -13 of the pro- 
sequence may form a disulfide bond with the cysteine residue References 
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